...
首页> 外文期刊>Electronic Journal of Biotechnology >Mannheimia haemolytica growth and leukotoxin production for vaccine manufacturing – A bioprocess review
【24h】

Mannheimia haemolytica growth and leukotoxin production for vaccine manufacturing – A bioprocess review

机译:用于疫苗生产的溶血曼海姆氏菌的生长和白细胞毒素的生产–生物过程评论

获取原文

摘要

Mannheimia haemolytica leukotoxin (LKT) is a known cause of bovine respiratory disease (BRD) which results in severe economic losses in the cattle industry (up to USD 1 billion per year in the USA). Vaccines based on LKT offer the most promising measure to contain BRD outbreaks and are already commercially available. However, insufficient LKT yields, predominantly reflecting a lack of knowledge about the LKT expression process, remain a significant engineering problem and further bioprocess optimization is required to increase process efficiency. Most previous investigations have focused on LKT activity and cell growth, but neither of these parameters defines reliable criteria for the improvement of LKT yields. In this article, we review the most important process conditions and operational parameters (temperature, pH, substrate concentration, dissolved oxygen level, medium composition and the presence of metabolites) from a bioprocess engineering perspective, in order to maximize LKT yields.
机译:溶血性曼纽海菌白细胞毒素(LKT)是牛呼吸道疾病(BRD)的已知病因,在牛业造成严重的经济损失(美国每年高达10亿美元)。基于LKT的疫苗提供了遏制BRD爆发的最有希望的措施,并且已经在市场上出售。但是,LKT产量不足,主要反映出对LKT表达过程缺乏了解,仍然是一个重要的工程问题,需要进一步的生物过程优化来提高过程效率。以前的大多数研究都集中在LKT活性和细胞生长上,但是这些参数均未定义提高LKT产量的可靠标准。在本文中,我们从生物工艺工程的角度回顾了最重要的工艺条件和操作参数(温度,pH,底物浓度,溶解氧水平,培养基成分和代谢产物的存在),以使LKT产量最大化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号